Syndicate content

Archive - Jul 2016

Date
  • All
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31

July 18th

BioQuick News Says Dump Trump Now !

One only has to view the 30-second video (see below) of Donald Trump mocking a disabled reporter to conclude that Mr. Trump has absolutely no place in the sacred office of President of the United States of America. America was born from the urge to always do what is right, regardless of the cost or consequence; to always stand up to power to protect the oppressed and the downtrodden. You need not have one single nickel to qualify for President of the United States; what you do need is courage, honor, and the driving desire to always do what is right. Hundreds of thousands of US citizens have fought and died to protect and preserve the sacred values that are at the core of America's unique existence and place in the world. While Trump apparently feels quite free to mock a disabled reporter who had the nerve to ask him a probing question, he is the last person to get involved in a real fight. Much like his much shorter (5'8") forebear Dick Cheney, Trump avoided the Vietnam War draft four times and finally secured a highly dubious permanent deferment on the basis of an obscure foot problem. He is a mean school-yard bully with no understanding of true honor. BioQuick News, founded and published by the eldest son of a man who won a bronze star for battlefield reporting in WWII, says "Dump Trump Now."

[Video of Trump mocking disabled reporter]

July 3rd

Women with BRCA1 Gene Mutation at Higher Risk of Uncommon, But Deadly, Uterine Cancer

Women who carry the BRCA1 gene mutation that dramatically increases their risk of breast and ovarian cancers are also at higher risk for a lethal form of uterine cancer, according to a study led by a Duke Cancer Institute researcher. This newly defined risk - the first to show a conclusive link between the BRCA1 gene mutation and a small, but significant chance, of developing an aggressive uterine cancer - could become a consideration in weighing treatment options. Currently, women with the BRCA1 mutation often have preventive surgeries to remove both breasts, as well as their ovaries and fallopian tubes, based on studies showing that the gene mutation elevates their risk for cancers in those organs. But conflicting evidence has created controversy over the need to remove the uterus. Smaller studies identified a link between the gene mutation and uterine cancer, but the evidence to change practice has hinged on results from a well-designed study using a larger patient population from multiple sites. "This is the study that has been needed," said lead author Noah D. Kauff, M.D., who leads the Clinical Cancer Genetics Program at the Duke Cancer Institute. "Our study presents the strongest evidence to date that women with this genetic mutation should at least discuss with their doctors the option of having a hysterectomy along with removal of their ovaries and fallopian tubes." In the current study, published online on June 30, 2016 in the journal JAMA Oncology, Dr. Kauff and colleagues from nine other institutions in the U.S. and the United Kingdom analyzed data from 1,083 women. All had BRCA1 or BRCA2 genetic mutations, had undergone removal of their ovaries and fallopian tubes, and were followed for a median 5.1 years.

Artificial Pancreas Likely Available by 2018

The artificial pancreas -- a device which monitors blood glucose in patients with type 1 diabetes and then automatically adjusts levels of insulin entering the body -- is likely to be available by 2018, conclude authors of a review article published online on June 30, 2016 in Diabetologia (the journal of the European Association for the Study of Diabetes). The open-access article is titled “Coming of Age: the Artificial Pancreas for Type 1 Diabetes.” Issues such as speed of action of the forms of insulin used, reliability, convenience, and accuracy of glucose monitors, plus cybersecurity to protect devices from hacking, are among the issues that are being addressed. Currently available technology allows insulin pumps to deliver insulin to people with diabetes after taking a reading or readings from glucose meters, but these two components are separate. It is the joining together of both parts into a “closed loop” that makes an artificial pancreas, explain authors Dr. Roman Hovorka and Dr. Hood Thabit of the University of Cambridge, UK. "In trials to date, users have been positive about how use of an artificial pancreas gives them 'time off' or a 'holiday' from their diabetes management, because the system is managing their blood sugar effectively without the need for constant monitoring by the user," the authors say. One part of the clinical need for the artificial pancreas is the variability of insulin requirements between and within individuals -- on one day a person could use one third of their normal requirements, and on another three times what they normally would. This is dependent on the individual, their diet, their physical activity, and other factors.